PT2441766E - Di-hidrato de cloridrato de nalmefeno - Google Patents

Di-hidrato de cloridrato de nalmefeno Download PDF

Info

Publication number
PT2441766E
PT2441766E PT121502660T PT12150266T PT2441766E PT 2441766 E PT2441766 E PT 2441766E PT 121502660 T PT121502660 T PT 121502660T PT 12150266 T PT12150266 T PT 12150266T PT 2441766 E PT2441766 E PT 2441766E
Authority
PT
Portugal
Prior art keywords
hydrochloride dihydrate
nalmefene hydrochloride
nalmefene
dihydrate
hydrochloride
Prior art date
Application number
PT121502660T
Other languages
English (en)
Portuguese (pt)
Inventor
Carla De Faveri
Florian Anton Martin Huber
Heidi Lopez De Diego
Original Assignee
Lundbeck & Co As H
Biotie Therapies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41571731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2441766(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H, Biotie Therapies Corp filed Critical Lundbeck & Co As H
Publication of PT2441766E publication Critical patent/PT2441766E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
PT121502660T 2008-12-05 2009-12-04 Di-hidrato de cloridrato de nalmefeno PT2441766E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12013208P 2008-12-05 2008-12-05
DKPA200801729 2008-12-05

Publications (1)

Publication Number Publication Date
PT2441766E true PT2441766E (pt) 2014-08-05

Family

ID=41571731

Family Applications (2)

Application Number Title Priority Date Filing Date
PT121502660T PT2441766E (pt) 2008-12-05 2009-12-04 Di-hidrato de cloridrato de nalmefeno
PT09771286T PT2300479E (pt) 2008-12-05 2009-12-04 Di-hidrato de cloridrato de nalmefeno

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT09771286T PT2300479E (pt) 2008-12-05 2009-12-04 Di-hidrato de cloridrato de nalmefeno

Country Status (30)

Country Link
US (2) US8530495B2 (enExample)
EP (2) EP2441766B1 (enExample)
JP (3) JP6055183B2 (enExample)
KR (2) KR20110089333A (enExample)
CN (2) CN102325778B (enExample)
AR (1) AR074507A1 (enExample)
AT (1) ATE546453T1 (enExample)
AU (1) AU2009321898B2 (enExample)
BR (1) BRPI0922774B8 (enExample)
CA (1) CA2744932C (enExample)
CL (1) CL2011001331A1 (enExample)
CO (1) CO6362012A2 (enExample)
CY (2) CY1112643T1 (enExample)
DK (2) DK2441766T3 (enExample)
EA (1) EA018948B1 (enExample)
ES (2) ES2380297T3 (enExample)
HR (2) HRP20120247T1 (enExample)
IL (1) IL213112A (enExample)
MX (1) MX2011005865A (enExample)
MY (1) MY149028A (enExample)
NZ (1) NZ593874A (enExample)
PL (2) PL2441766T3 (enExample)
PT (2) PT2441766E (enExample)
RS (2) RS52255B (enExample)
SG (1) SG171910A1 (enExample)
SI (2) SI2441766T1 (enExample)
SM (2) SMT201200014B (enExample)
TW (1) TWI465450B (enExample)
UA (1) UA102128C2 (enExample)
WO (1) WO2010063292A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
JP2019031524A (ja) * 2008-12-05 2019-02-28 ハー・ルンドベック・アクチエゼルスカベット ナルメフェン塩酸塩二水和物
TWI560170B (en) * 2011-12-06 2016-12-01 Lundbeck & Co As H Process for recovery of nalmefene hydrochloride
AR090916A1 (es) 2012-05-03 2014-12-17 Lundbeck & Co As H Metodo para la fabricacion de naltrexona
US20140005217A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
WO2014170353A1 (en) * 2013-04-17 2014-10-23 H. Lundbeck A/S Nalmefene for treatment of patients with sleep disorder
US20160058754A1 (en) * 2013-04-17 2016-03-03 H. Lundbeck A/S Nalmefene for Treatment of Patients with Anxiety Disorder
AR096851A1 (es) * 2013-07-11 2016-02-03 H Lundbeck As Sales que no forman hidratos ni solvatos de nalmefeno
TW201625252A (zh) 2014-04-22 2016-07-16 大塚製藥股份有限公司 藥物
TW202134236A (zh) 2014-06-12 2021-09-16 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
CN105646508B (zh) * 2016-02-17 2018-02-27 南京卓康医药科技有限公司 一种盐酸纳美芬一水合物的制备方法
WO2019022274A1 (ko) * 2017-07-28 2019-01-31 동아대학교 산학협력단 Pauf 단백질에 특이적으로 결합하는 항체 및 이의 용도
US10927121B1 (en) 2019-12-20 2021-02-23 Southwest Research Institute Technologies for removing residual solvent from nalmefene hydrochloride and producing crystalline nalmefene hydrochloride monohydrate, monosolvate, or crystalline nalmefene hydrochloride dihydrate
CN111875530A (zh) * 2020-08-17 2020-11-03 浙江朗华制药有限公司 一种普拉西坦水合物晶体及其制备方法
WO2022165040A1 (en) 2021-01-28 2022-08-04 Rhodes Technologies Process for crystallizing nalmefene hydrochloride
CN113354652A (zh) * 2021-06-24 2021-09-07 无锡济煜山禾药业股份有限公司 一种盐酸纳美芬合成方法
CN117843650A (zh) * 2023-12-27 2024-04-09 南京海纳医药科技股份有限公司 一种盐酸纳美芬的精制方法
CN117986261B (zh) * 2024-04-02 2024-06-18 成都瑞尔医药科技有限公司 一种盐酸纳美芬母液的回收套用方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535157A (en) 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US4751307A (en) 1985-01-17 1988-06-14 Mallinckrodt, Inc. Wittig-reaction processes
JPH07206857A (ja) * 1993-12-28 1995-08-08 Synthelabo Sa アルフゾシン塩酸塩の二水和物
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
ES2177373B1 (es) * 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
CH693586A8 (de) * 2002-10-14 2003-12-15 Roche Consumer Health Ag Darreichungsform von Ibuprofen-Natrium.
FR2861299B1 (fr) * 2003-10-28 2006-01-27 Pf Medicament Compositions pharmaceutiques a base de derives d'idasoxan sous formes polymorphes
PL1708690T3 (pl) * 2003-11-17 2017-01-31 Biomarin Pharmaceutical Inc. Leczenie fenyloketonurii za pomocą BH4
MY139797A (en) * 2004-11-29 2009-10-30 Kowa Co (s)-(-)-1-(4-fluoroisoquinolin-5-yl)sulfonyl-2-methyl-1, 4-homopiperazine hydrochloride dihydrate
CN100536848C (zh) * 2005-07-13 2009-09-09 北京易明康元医药科技有限公司 稳定的盐酸纳美芬注射液及其制备方法
GB2447016A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
GB2447013A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition containing buprenorphone and nalmefene
CA2707757C (en) 2007-03-06 2017-01-03 Peter X. Wang Process for the preparation of quaternary n-alkyl morphinan alkaloid salts
WO2008127618A1 (en) * 2007-04-12 2008-10-23 Mallinckrodt Inc. Crystalline and amorphous forms of naltrexone hydrochloride
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate

Also Published As

Publication number Publication date
US20130338365A1 (en) 2013-12-19
CN104211707B (zh) 2017-04-12
EA201170753A1 (ru) 2011-12-30
PL2300479T3 (pl) 2012-06-29
CN102325778B (zh) 2014-08-13
UA102128C2 (en) 2013-06-10
TW201022273A (en) 2010-06-16
HRP20120247T1 (hr) 2012-05-31
EP2300479A1 (en) 2011-03-30
EA018948B1 (ru) 2013-11-29
IL213112A0 (en) 2011-07-31
US8530495B2 (en) 2013-09-10
EP2441766A1 (en) 2012-04-18
CY1115381T1 (el) 2017-01-04
JP2015134785A (ja) 2015-07-27
MX2011005865A (es) 2011-09-06
HK1205108A1 (en) 2015-12-11
CN102325778A (zh) 2012-01-18
BRPI0922774B1 (pt) 2020-10-13
ES2488165T3 (es) 2014-08-26
CA2744932A1 (en) 2010-06-10
EP2300479B1 (en) 2012-02-22
TWI465450B (zh) 2014-12-21
ES2380297T3 (es) 2012-05-10
EP2441766B1 (en) 2014-06-25
JP2017025079A (ja) 2017-02-02
US8754217B2 (en) 2014-06-17
KR20110089333A (ko) 2011-08-05
JP6591944B2 (ja) 2019-10-16
WO2010063292A1 (en) 2010-06-10
HRP20140648T1 (hr) 2014-09-26
AR074507A1 (es) 2011-01-19
JP2012510954A (ja) 2012-05-17
SI2441766T1 (sl) 2014-12-31
NZ593874A (en) 2013-02-22
DK2300479T3 (da) 2012-03-26
SMT201200014B (it) 2012-07-10
IL213112A (en) 2013-06-27
ATE546453T1 (de) 2012-03-15
JP6591759B2 (ja) 2019-10-16
BRPI0922774B8 (pt) 2021-05-25
SI2300479T1 (sl) 2012-07-31
BRPI0922774A2 (pt) 2017-07-11
AU2009321898B2 (en) 2014-10-02
US20110251228A1 (en) 2011-10-13
CL2011001331A1 (es) 2011-08-26
PT2300479E (pt) 2012-04-10
SG171910A1 (en) 2011-07-28
CA2744932C (en) 2013-05-07
CN104211707A (zh) 2014-12-17
JP6055183B2 (ja) 2016-12-27
AU2009321898A1 (en) 2011-07-14
RS53415B (sr) 2014-12-31
KR20170008893A (ko) 2017-01-24
CY1112643T1 (el) 2016-02-10
CO6362012A2 (es) 2012-01-20
MY149028A (en) 2013-06-28
DK2441766T3 (da) 2014-07-21
RS52255B (sr) 2012-10-31
SMT201400113B (it) 2014-11-10
PL2441766T3 (pl) 2014-09-30

Similar Documents

Publication Publication Date Title
IL213112A0 (en) Nalmefene hydrochloride dihydrate
GB201020970D0 (en) Early entry
GB0810179D0 (en) Object location
IL210548A0 (en) Spiroaminodihydrothiazine derivatives
ZA201102113B (en) Morphinan compounds
ZA201100799B (en) Imidazopyridin-2-one derivatives
SG10201506608RA (en) 3-deazaneplanocin derivatives
IL210406A0 (en) Pyrrolopyridinylpyrimidin - 2 - ylamine derivatives
ZA201102449B (en) Morpholinopurine derivatives
GB0921999D0 (en) Early entry
IL210869A0 (en) Imidazothiadiazoles derivatives
IL208336A0 (en) Pyrisazinone derivatives
ZA201102606B (en) Mortar
ZA201100948B (en) Acylaminobenzamide derivatives
IL210164A0 (en) Thiazolylpiperidine derivatives
ZA201105050B (en) Quinazolinamide derivatives
ZA201008052B (en) 2-phenyl-4-cyclopropyl-pyrimidine derivatives
GB0922083D0 (en) Early entry
GB0920030D0 (en) Early entry
AP2009004881A0 (en) Poly-TLR antagonist
IL213051A0 (en) Difluorophenyldiacylhydrazide derivatives
GB0803933D0 (en) Pre-Loading
GB0803793D0 (en) Pre-Loading
GB0808765D0 (en) Location
HU0800376D0 (en) Sulfonyl-quinoline derivatives